Moreover, secretory leukocyte protease inhibitor (SLPI) gene and protein expression is lower in metastatic versus non-metastatic HNSCC, and thus, SLPI may be a potential biomarker for identifying individuals at risk of developing metastases [42]. The gene discussed is SLPI; the disease is head and neck squamous cell carcinoma.